Voleon Capital Management LP Purchases Shares of 14,705 Edwards Lifesciences Corporation $EW

Key Points

• Voleon Capital Management LP acquired 14,705 shares of Edwards Lifesciences Corporation for about $1.066 million during the first quarter of the year.
• Institutional investors hold 79.46% of Edwards Lifesciences' stock, indicating strong interest from large financial entities.
• Edwards Lifesciences reported a quarterly EPS of $0.67, surpassing estimates, and showed an 11.9% year-over-year revenue increase.

Voleon Capital Management LP purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 14,705 shares of the medical research company's stock, valued at approximately $1,066,000.

A number of other institutional investors and hedge funds have also bought and sold shares of EW. Everstar Asset Management LLC purchased a new stake in shares of Edwards Lifesciences during the first quarter valued at approximately $1,121,000. USS Investment Management Ltd boosted its stake in shares of Edwards Lifesciences by 1.6% during the first quarter. USS Investment Management Ltd now owns 120,055 shares of the medical research company's stock valued at $8,700,000 after purchasing an additional 1,884 shares during the period. UniSuper Management Pty Ltd boosted its stake in shares of Edwards Lifesciences by 2.8% during the first quarter. UniSuper Management Pty Ltd now owns 52,045 shares of the medical research company's stock valued at $3,772,000 after purchasing an additional 1,400 shares during the period. Parkman Healthcare Partners LLC boosted its stake in shares of Edwards Lifesciences by 38.3% during the first quarter. Parkman Healthcare Partners LLC now owns 200,819 shares of the medical research company's stock valued at $14,555,000 after purchasing an additional 55,605 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Edwards Lifesciences by 1.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 100,887 shares of the medical research company's stock valued at $7,311,000 after purchasing an additional 1,442 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $80.28 on Tuesday. The stock has a fifty day moving average of $78.80 and a 200 day moving average of $75.26. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00. The firm has a market capitalization of $47.13 billion, a price-to-earnings ratio of 11.55, a PEG ratio of 3.90 and a beta of 1.07. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on EW shares. Robert W. Baird increased their price objective on Edwards Lifesciences from $78.00 to $79.00 and gave the company a "neutral" rating in a research note on Friday, July 25th. Daiwa America raised Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 29th. Truist Financial increased their price objective on Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a research note on Friday, July 25th. Wells Fargo & Company increased their price objective on Edwards Lifesciences from $84.00 to $88.00 and gave the company an "overweight" rating in a research note on Thursday, August 7th. Finally, Barclays increased their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the company an "overweight" rating in a research note on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Edwards Lifesciences has an average rating of "Moderate Buy" and an average target price of $85.90.

Insider Buying and Selling at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the transaction, the insider owned 206,900 shares of the company's stock, valued at $15,565,087. The trade was a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,014 shares of company stock valued at $1,698,844 in the last three months. Insiders own 0.34% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.